132 related articles for article (PubMed ID: 34071914)
61. Ligands for mapping alphavbeta3-integrin expression in vivo.
Schottelius M; Laufer B; Kessler H; Wester HJ
Acc Chem Res; 2009 Jul; 42(7):969-80. PubMed ID: 19489579
[TBL] [Abstract][Full Text] [Related]
62. New [99mTc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor-positive tumors.
García Garayoa E; Schweinsberg C; Maes V; Rüegg D; Blanc A; Bläuenstein P; Tourwé DA; Beck-Sickinger AG; Schubiger PA
Q J Nucl Med Mol Imaging; 2007 Mar; 51(1):42-50. PubMed ID: 17372572
[TBL] [Abstract][Full Text] [Related]
63. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
[TBL] [Abstract][Full Text] [Related]
64. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
65. PEG spacers of different length influence the biological profile of bombesin-based radiolabeled antagonists.
Jamous M; Tamma ML; Gourni E; Waser B; Reubi JC; Maecke HR; Mansi R
Nucl Med Biol; 2014 Jul; 41(6):464-70. PubMed ID: 24780298
[TBL] [Abstract][Full Text] [Related]
66. Novel DOTA-neurotensin analogues for 111In scintigraphy and 68Ga PET imaging of neurotensin receptor-positive tumors.
Alshoukr F; Prignon A; Brans L; Jallane A; Mendes S; Talbot JN; Tourwé D; Barbet J; Gruaz-Guyon A
Bioconjug Chem; 2011 Jul; 22(7):1374-85. PubMed ID: 21662976
[TBL] [Abstract][Full Text] [Related]
67. Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation.
Brillouet S; Dorbes S; Courbon F; Picard C; Delord JP; Benoist E; Poirot M; Mestre-Voegtlé B; Silvente-Poirot S
Bioorg Med Chem; 2010 Jul; 18(14):5400-12. PubMed ID: 20542702
[TBL] [Abstract][Full Text] [Related]
68. [
Lau J; Kwon D; Rousseau E; Zhang Z; Zeisler J; Uribe CF; Kuo HT; Zhang C; Lin KS; Bénard F
Mol Pharm; 2019 Nov; 16(11):4688-4695. PubMed ID: 31545614
[TBL] [Abstract][Full Text] [Related]
69. Preclinical evaluation of new GnRH-I receptor radionuclide therapy with
Zoghi M; Attar Nosrati S; Rogni F; Shirvani G; Johari Daha F
J Labelled Comp Radiopharm; 2019 Jun; 62(7):310-320. PubMed ID: 31033025
[TBL] [Abstract][Full Text] [Related]
70. Radiolabeled antagonistic bombesin peptidomimetics for tumor targeting.
Valverde IE; Huxol E; Mindt TL
J Labelled Comp Radiopharm; 2014 Apr; 57(4):275-8. PubMed ID: 24327435
[TBL] [Abstract][Full Text] [Related]
71. Multifactorial diagnostic NIR imaging of CCK2R expressing tumors.
Kossatz S; Béhé M; Mansi R; Saur D; Czerney P; Kaiser WA; Hilger I
Biomaterials; 2013 Jul; 34(21):5172-80. PubMed ID: 23591397
[TBL] [Abstract][Full Text] [Related]
72. GRP receptor-targeted PET of a rat pancreas carcinoma xenograft in nude mice with a 68Ga-labeled bombesin(6-14) analog.
Schuhmacher J; Zhang H; Doll J; Mäcke HR; Matys R; Hauser H; Henze M; Haberkorn U; Eisenhut M
J Nucl Med; 2005 Apr; 46(4):691-9. PubMed ID: 15809493
[TBL] [Abstract][Full Text] [Related]
73. Dimeric DOTA-alpha-melanocyte-stimulating hormone analogs: synthesis and in vivo characteristics of radiopeptides with high in vitro activity.
Bapst JP; Froidevaux S; Calame M; Tanner H; Eberle AN
J Recept Signal Transduct Res; 2007; 27(5-6):383-409. PubMed ID: 18097939
[TBL] [Abstract][Full Text] [Related]
74. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
75. The Cholecystokinin Type 2 Receptor, a Pharmacological Target for Pain Management.
Bernard A; Danigo A; Bourthoumieu S; Mroué M; Desmoulière A; Sturtz F; Rovini A; Demiot C
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832967
[TBL] [Abstract][Full Text] [Related]
76. SPECT/CT Imaging, Biodistribution and Radiation Dosimetry of a
Sachindra S; Hellberg T; Exner S; Prasad S; Beindorff N; Rogalla S; Kimura R; Gambhir SS; Wiedenmann B; Grötzinger C
Front Oncol; 2021; 11():684713. PubMed ID: 34136410
[TBL] [Abstract][Full Text] [Related]
77. Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.
Holzleitner N; Fischer S; Maniyankerikalam I; Beck R; Lapa C; Wester HJ; Günther T
EJNMMI Res; 2024 Mar; 14(1):23. PubMed ID: 38429609
[TBL] [Abstract][Full Text] [Related]
78. Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs.
Holzleitner N; Günther T; Daoud-Gadieh A; Lapa C; Wester HJ
EJNMMI Res; 2023 Jul; 13(1):65. PubMed ID: 37421545
[TBL] [Abstract][Full Text] [Related]
79. An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 2: Overall Variabilities in Absorbed Dose.
Brosch-Lenz J; Ke S; Wang H; Frey E; Dewaraja YK; Sunderland J; Uribe C
J Nucl Med; 2023 Jul; 64(7):1109-1116. PubMed ID: 37024302
[TBL] [Abstract][Full Text] [Related]
80. Radionuclides in Diagnostics and Therapy of Malignant Tumors: New Development.
Tolmachev V; Vorobyeva A
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
